RESEARCH ANTIBODIES MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Growing Investments & Increasing product launches

Increased investments from both public and private sectors in life science R&D can drive the research antibodies market growth. This is fueled by the recognition of the importance of basic research in fields like immunology, cancer biology, genetics, and neuroscience. The development of novel antibody-based therapeutics and diagnostics is attracting substantial capital, leading to growing demand for research antibodies in academic and industry labs. This trend is supported by sophisticated core facilities in leading research institutions, indicating sustained growth potential for the market. Product approvals by industry participants can drive the research antibody market growth during the forecast period. Tepezza (TM) (teprotumumab-trbw), a therapeutic monoclonal antibody for the treatment of thyroid eye disease (TED), was approved by the U.S. Food and Drug Administration on January 21, 2020. Horizon Therapeutics plc is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines, and it had developed Tepezza (TM) (teprotumumab-trbw). TED is an unusual autoimmune disorder that is severe, progressive, and potentially blinding. It is characterized by pain, inflammation, deformity of the face, diplopia (double vision), proptosis (eye bulging), and blurred vision. The FDA (Food and Drug Administration) in the U.S. had approved Tepezza as the sole drug for TED patients.